Comparison of gastroparesis risk across different weight loss modalities including GLP-1 drugs and bariatric surgery helps quantify this GI complication by treatment approach.
Key findingComparison of gastroparesis risk across different weight loss modalities including GLP-1 drugs and b
What the researchers found
Comparison of gastroparesis risk across different weight loss modalities including GLP-1 drugs and bariatric surgery helps quantify this GI complication by treatment approach.
Why it matters
Relevant to peptide therapeutics.
The numbers in context
Specific incidence rates not detailed in abstract; study used a large commercial claims database for comparison.
How the study worked
In publication.
Who was studied
Adults with obesity without type 2 diabetes treated with semaglutide, bupropion-naltrexone, or sleeve gastrectomy
What this study cannot tell us
In publication.
How to read the evidence
Based on design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide evidence.
Questions still open
- Long-term implications?
- Evidence comparison?
- Next steps?
Common questions
What does this mean?
How reliable?
Read the original research
Comparing the risk of gastroparesis following different modalities for treating obesity: semaglutide versus bupropion-naltrexone versus sleeve gastrectomy - a retrospective cohort study.
BMJ open gastroenterology, 12(1)
Citation
Aneke-Nash, Chino; Hung, Kay Su; Wall-Wieler, Elizabeth; Zheng, Feibi; Sharaiha, Reem Z. (2025). Comparing the risk of gastroparesis following different modalities for treating obesity: semaglutide versus bupropion-naltrexone versus sleeve gastrectomy - a retrospective cohort study.. BMJ open gastroenterology, 12(1). https://doi.org/10.1136/bmjgast-2024-001704